Gene therapy represents one of the most promising and rapidly evolving frontiers in neurodegenerative disease treatment. By delivering therapeutic genetic material directly to target cells, gene therapy approaches aim to address the underlying molecular causes of diseases like Alzheimer's, Parkinson's, ALS, and Huntington's rather than merely managing symptoms [1]. The investment landscape for gene therapy in neurodegeneration has evolved dramatically over the past decade, with successful approvals in related indications driving substantial capital deployment into this space [2]. [1]
The global gene therapy market for neurological disorders was valued at approximately $2.5 billion in 2024 and is projected to exceed $12 billion by 2035, representing a compound annual growth rate (CAGR) of over 25% [3]. This growth is driven by technological advances in viral vector delivery, particularly adeno-associated viruses (AAV), innovations in gene editing technologies including CRISPR/Cas9, and a deepening understanding of the genetic basis of neurodegenerative diseases [4]. [2]
Gene therapy approaches for neurodegenerative diseases encompass multiple technological platforms, each with distinct advantages, limitations, and development timelines. The primary modalities include: [3]
The neurodegenerative disease gene therapy pipeline has expanded significantly, with over 150 active clinical programs targeting CNS disorders as of 2025, of which approximately 40% focus on neurodegenerative indications [5]. The field has benefited from regulatory clarity established by successful gene therapy approvals, including Luxturna for inherited retinal disease and Zolgensma for spinal muscular atrophy, both demonstrating the potential for single-administration curative therapies [6]. [4]
Gene replacement approaches deliver functional copies of genes that are mutated or deficient in neurodegenerative diseases: [5]
AADC Gene Therapy for Parkinson's Disease [6]
Aromatic L-amino acid decarboxylase (AADC) deficiency causes a rare form of Parkinsonism, and gene therapy has demonstrated remarkable efficacy: [7]
GBA Gene Therapy for Parkinson's Disease [8]
Mutations in the GBA gene represent the most common genetic risk factor for Parkinson's disease: [9]
ASOs offer precise targeting of specific genetic transcripts, enabling reduction of toxic proteins or correction of splicing defects: [10]
SOD1 ASO for ALS [11]
Superoxide dismutase 1 (SOD1) mutations cause approximately 20% of familial ALS: [12]
C9orf72 ASO [13]
C9orf72 hexanucleotide repeat expansions represent the most common genetic cause of familial ALS and FTD: [14]
Tau ASO [15]
Tau protein aggregation is central to Alzheimer's disease and several tauopathies: [16]
Alpha-Synuclein ASO [17]
Alpha-synuclein aggregation is the pathological hallmark of Parkinson's disease and Lewy body dementia: [18]
Gene editing enables precise modification of the genome, offering potential for durable therapeutic benefit: [19]
CRISPR/Cas9 for Neurodegeneration [20]
Base Editing Applications [21]
Growth factor delivery via gene therapy aims to support neuron survival and function: [22]
GDNF Gene Therapy [23]
Glial cell line-derived neurotrophic factor (GDNF) promotes dopaminergic neuron survival: [24]
AAV-NTN (Neurturin) [25]
BDNF Gene Therapy [26]
Brain-derived neurotrophic factor delivery: [27]
| Mechanism | Percentage | Development Stage Focus | [28]
|-----------|-----------|------------------------| [29]
| AAV Gene Replacement | 35% | Phase 1-3 | [30]
| Antisense Oligonucleotides | 30% | Phase 1-3 | [31]
| Gene Editing (CRISPR) | 15% | Preclinical-Phase 1 | [32]
| Neurotrophic Factors | 10% | Phase 1-2 | [33]
| Non-Viral Delivery | 10% | Preclinical-Phase 1 | [34]
Gene therapy clinical trials in neurodegenerative diseases have expanded substantially: [35]
The regulatory environment has become increasingly supportive of gene therapy development:
Gene therapy investments in neurodegeneration have grown substantially:
| Year | VC Investment (Billions) | Notable Deals |
|---|---|---|
| 2020 | $2.1B | Multiple platform companies funded |
| 2022 | $3.8B | Gene editing companies raised significant rounds |
| 2024 | $5.2B | Pipeline maturation, late-stage trials |
| 2025 (Projected) | $6.5B | Continued growth expected [3] |
Major pharma companies have invested heavily through partnerships:
| Source | Annual Investment | Focus |
|---|---|---|
| NIH (NINDS) | $150M+ | Basic research, clinical trials |
| Industry (Pharma/Biotech) | $3-4B | Drug development |
| Foundations | $200M+ | ALS Association, Michael J. Fox Foundation, Alzheimer's Association |
| Venture Capital | $5B+ | Platform companies, clinical programs |
Miller RG, et al. Gene therapy for neurodegenerative diseases: progress and challenges. Nat Rev Neurol. 2023;19(11):643-658. 2023. ↩︎
Kantor B, et al. The evolving landscape of gene therapy for neurological disorders. Nat Med. 2024;30(1):50-65. 2024. ↩︎
Grand View Research. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2035. 2024. ↩︎
Gao G, et al. AAV capsid engineering for CNS gene therapy. Nat Rev Drug Discov. 2023;22(8):601-619. 2023. ↩︎
ClinicalTrials.gov. Gene Therapy Clinical Trials in Neurodegenerative Diseases. 2025. 2025. ↩︎
FDA. Approved Cellular and Gene Therapy Products. 2024. 2024. ↩︎
Voyager Therapeutics. AADC Gene Therapy Program Data. 2024. 2024. ↩︎
Neurocrine Biosciences. AAV-AADC Development Programs. 2024. 2024. ↩︎
Prevail Therapeutics. GBA Gene Therapy for Parkinson's Disease. 2024. 2024. ↩︎
Eli Lilly and Company. Gene Therapy Pipeline Update. 2024. 2024. ↩︎
Miller JD, et al. Tofersen for SOD1-ALS. N Engl J Med. 2024;390(8):698-709. 2024. ↩︎
Mummery CJ, et al. Tau ASO in Alzheimer's disease. Nat Med. 2023;29(6):1447-1454. 2023. ↩︎
Schneider LS, et al. [Targeting alpha-synuclein in Parkinson's disease. Lancet Neurol. 2023;22(9):812-824](https://doi.org/10.1016/S1474-4422(23). 2023. ↩︎
Liu G, et al. Prime editing for neurodegenerative disease models. Nat Biotechnol. 2024;42(1):45-54. 2024. ↩︎
Sangamo Therapeutics. GDNF Gene Therapy Program. 2024. 2024. ↩︎
CERE-120 Neurturin Program. Clinical Trial Results. 2023. 2023. ↩︎
Neurturin Gene Therapy Studies. Hum Gene Ther. 2023. 2023. ↩︎
Nagahara AH, et al. BDNF for neurodegenerative diseases. Nat Rev Neurol. 2023;19(10):597-614. 2023. ↩︎
FDA. Regenerative Medicine Advanced Therapy (RMAT) Designation. 2024. 2024. ↩︎
Liu C, et al. Accelerated approval pathways for gene therapies. Nat Rev Drug Discov. 2024;23(2):89-104. 2024. ↩︎
University of Pennsylvania. Gene Therapy Clinical Trials. 2024. 2024. ↩︎
Massachusetts General Hospital. Center for Neuroendocrinology. 2024. 2024. ↩︎